Molecular GeneticsOncology

KRAS Gene Analysis

Normal Range
Wild Type (No Mutation Detected)
Sample Type
Tissue Biopsy
Fasting
No
Unit
N/A

Function

The KRAS gene analysis looks for mutations in the Kirsten rat sarcoma viral oncogene homolog. This gene provides instructions for making a protein that regulates cell division. In many cancers, mutations keep this protein 'switched on,' causing cells to grow and divide uncontrollably.

Why it is Ordered

This is a 'companion diagnostic' test. It is primarily ordered for patients with metastatic colorectal cancer or non-small cell lung cancer (NSCLC). Knowing the KRAS status is essential before starting targeted therapies like EGFR inhibitors (e.g., Cetuximab or Panitumumab). If a KRAS mutation is present, these specific drugs will not work, saving the patient from unnecessary side effects and costs.

Associated Conditions

  • Colorectal Cancer: Roughly 40% of cases involve KRAS mutations.
  • Non-Small Cell Lung Cancer: KRAS is a common driver mutation, particularly G12C.
  • Pancreatic Cancer: Over 90% of pancreatic adenocarcinomas harbor KRAS mutations.
  • Cholangiocarcinoma: Also frequently associated with KRAS alterations.

Check Your Result

Check Your Result

Interactive
N/A

Enter your lab result to see where you stand compared to the standard reference range.

Why Context Matters

Genetic results depend heavily on the quality of the tumor sample. If the biopsy contains too much healthy tissue and not enough 'tumor cell cellularity,' a mutation might be missed (false negative). Different labs use different sequencing depths (Sanger vs. NGS); a second opinion using Next-Generation Sequencing (NGS) is often recommended if earlier tests were inconclusive.

Lab ranges are statistical averages, not biological laws. "Normal" for a 20-year-old male isn't normal for a 60-year-old female.

Clinical References

Source-of-truth databases and clinical guidelines for KRAS Gene Analysis:

Research & Guidelines

Related Indicators

BCR/ABL Quantification

View Range

MGMT Methylation Test - Glioblastoma

View Range
DR

Medically Reviewed by Dr. Binoy Babu, MBBS

Board Certified Doctor • 10+ Years Clinical Experience

Dr. Babu is a practicing physician dedicated to empowering patients with clear, actionable medical information. He founded 2opi to bridge the gap between complex lab reports and patient understanding, ensuring everyone has access to a reliable second opinion.

Get Notified When Dr. Babu Is Available